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a  b  s  t  r  a  c  t
Introduction  &  objectives:  The  independent  effect  of  liver  biochemistries  as  a prognostic  factor  in patients
with  COVID-19  has  not  been  completely  addressed.  We  aimed  to evaluate  the  prognostic  value of  abnor-
mal  liver  tests  on  admission  of  hospitalized  patients  with  COVID-19.
Materials  & methods:  We  performed  a prospective  cohort  study  including  1611  hospitalized  patients  with
confirmed  SARS-CoV-2  infection  from  April  15,  2020  through  July  31, 2020  in 38 different  Hospitals  from
11  Latin  American  countries.  We  registered  clinical  and  laboratory  parameters,  including  liver  function
tests,  on  admission  and  during  hospitalization.  All  patients  were  followed  until  discharge  or  death.  We
fit  multivariable  logistic  regression  models,  further  post-estimation  effect  through  margins  and  inverse
probability  weighting.
Results: Overall,  57.8%  of  the patients  were  male  with  a  mean  age  of  52.3 years,  8.5%  had  chronic  liver
disease  and  3.4%  had  cirrhosis.  Abnormal  liver  tests  on  admission  were  present  on  45.2%  (CI  42.7–47.7)
of  the  cohort  (n  =  726).  Overall,  15.1%  (CI  13.4–16.9)  of  patients  died  (n  =  244).  Patients  with  abnormal
liver  tests  on  admission  presented  higher  mortality  18.7%  (CI  15.9–21.7),  compared  to  those  with  normal
liver  biochemistries  12.2%  (CI  10.1–14.6);  P  <  .0001).  After  excluding  patients  with  history  of  chronic
liver  disease,  abnormal  liver  tests  on  admission  were  independently  associated  with  death  [OR  1.5  (CI
1.1–2.0);  P = 0.01],  and  severe  COVID-19  (2.6  [2.0–3.3],  P <  .0001),  both  adjusted  by  age, gender,  diabetes,
pneumonia  and body  mass  index  >30.
Conclusions:  The  presence  of  abnormal  liver  tests  on admission  is  independently  associated  with  mortality
and  severe  COVID-19  in hospitalized  patients  with  COVID-19  infection  and  may  be  used as  surrogate
marker  of  inflammation.
Clinicaltrials.gov:  NCT04358380.
©  2020  Fundación  Clı́nica  Médica  Sur,  A.C.  Published  by  Elsevier  España,  S.L.U.  This  is an  open  access























admitted for a different condition and tested positive for COVID-19
during their hospitalization. Patients with high-clinical and epi-1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection causing Coronavirus disease 2019 (COVID-19) has been
associated with high mortality. The factors commonly associated
with worse prognosis are age greater than 60 years, presence of
diabetes, cardiovascular disease, and obesity [1,2]. While SARS-
CoV-2 is known to cause mainly pulmonary disease, the emerging
literature suggests that many extrapulmonary manifestations of
COVID-19 can also be present [3].
The liver might also represent a target organ for SARS-CoV-2
based on the findings that angiotensin-converting enzyme (ACE-2),
the major receptor of SARS-CoV-2, is expressed on cholangio-
cytes [4]. Liver abnormalities could be due to hypoxia-associated
metabolic derangements, drug-induced liver injury and hyper-
inflammation observed during cytokine storm, causing direct
cytopathic damage to the liver [5–7]. A recent systematic review
reported a 19% (range 1–53%) pooled prevalence of liver func-
tion abnormalities in COVID-19 patients [6,8]. However, studies
reporting liver injury in COVID-19 patients are retrospective, with
high clinical and statistical heterogeneity [6,9–13]. Most of these
studies described a substantial increase in the incidence of liver
injury after hospitalization. However, the impact of liver biochem-
istry parameters on admission, and the clinical course of COVID-19
remains uncertain. Hence, in hospitalized patients with COVID-19,
whether abnormal liver tests on admission may  be surrogate mark-
ers of inflammation and an independent prognostic factor is still
unknown.
Because of a later arrival of the COVID-19 pandemic in Latin
America, we had a unique opportunity to build a multi-national
prospective registry. Thus, we sought to evaluate the effect of





. Patients and methods
.1. Study design, setting and participating centers
This prospective cohort study was performed from April 15,
020 through July 31, 2020 in 38 different Hospitals from Argentina,
razil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala,
exico, Paraguay, Peru and Uruguay. The study was supported and
oordinated by the Latin American Association for the Study of
he Liver (ALEH), Viral Hepatitis Group of Interest and registered
n an open public registry (NCT04358380; www.clinicaltrials.gov).
ach Ethics Committee from all the participating centers approved
he study protocol, and was exempted from the need for informed
onsent from patients. The protocol followed the Strengthening
he Reporting of Observational Studies in Epidemiology (STROBE)
uidelines [14]. The study followed ethical standards (institutional
nd national) and those mandated by the Helsinki Declaration of
975, as revised in 2008. All authors had access to the study data,
eviewed, and approved the final version of this manuscript.
.2. Cohort characteristics and study variables
Eligibility criteria for enrolment included patients ≥17 years
ld, hospitalized with SARS-CoV-2 infection confirmed by the real-
ime polymerase method (RT-PCR) as per the local site-specific
rotocol. In asymptomatic cases, a nasopharyngeal swab was
btained according to surveillance algorithms from each coun-
ry (i.e. contact with positive subjects). We also included patientsemiological suspicion of SARS-CoV-2 but without RT-PCR testing
ere excluded. All eligible patients were enrolled at each clinical
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Table  1
Baseline characteristics of patients hospitalized for COVID-19.
Liver biochemistries
Total Normal Abnormal P
Variable N = 1611 N = 882 N = 729 Value
Age,  years (mean, ± SD) 52.3 (17.4) 50.7(18.2) 54.2 (16.1) 0.0001
Male  sex, n (%) 931 (57.8) 467 (52.9) 464 (63.6) <.0001
Comorbidities, n (%)
Hypertension 483 (29.9) 239 (27.1) 244 (33.5) 0.006
Diabetes 286 (17.7) 140 (15.9) 146 (20.0) 0.03
COPD/asthma 95 (5.9) 54 (6.1) 41 (5.7) 0.7
Cardiac disease 108 (6.7) 61 (6.9) 47 (6.4) 0.7
Cerebrovascular disease 33 (2.1) 24 (2.8) 9 (1.1) 0.03
HIV  16 (0.9) 6 (0.7) 10 (1.4) 0.2
Cancer 69 (4.3) 38 (4.3) 31 (4.2) 0.9
Chronic kidney disease 43 (2.8) 21 (2.4) 22 (3.0) 0.4
Body  Mass Index >30 277 (17.2) 125 (14.2) 152 (20.8) <.0001
Tobacco use, n (%) 326 (20.2) 178 (20.2) 148 (20.3) 0.9
Pregnant, n (%) 26 (1.6) 14 (1.6) 12 (1.6) 0.9
Solid  organ transplant recipient, n (%) 23 (1.4) 10 (1.0) 13 (1.9) 0.3
Chronic liver disease, n (%) 135 (8.5) 39 (4.4) 98 (13.4) <.0001
Cirrhosis, n (%) 55 (3.4) 15 (1.7) 40 (5.5) <.0001
Medications before admission
Antibiotics, n (%) 180 (11.7) 71 (8.0) 109 (14.9) <.0001
NSAIDs – paracetamol, n (%) 209 (12.9) 103 (11.7) 106 (14.5) 0.09
ACE-2 inhibitors, n (%) 188 (11.7) 99 (11.3) 89 (12.1) 0.6
Laboratory parameters on admission
Hemoglobin, mg/dL, mean (± SD) 13.7 (2.1) 13.7 (2.0) 13.8 (2.2) 0.4
WBC/mm3, mean (± SD) 8310 (5058) 7360 (4142) 9460 (5780) <.0001
Lymphocyte count <1500/mm3, n (%) 1031 (66.5) 528 (59.8) 503 (68.9) <.0001
Platelets, ×109/L, mean (± SD) 235.4 (97.7) 224.8 (86) 248.1(108) <.0001
Albumin, mg/dL, mean (± SD)a 3.9 (0.6) 4.0 (0.5) 3.7 (0.6) <.0001
INR,  mean (± SD) 1.1 (0.3) 1.0 (0.2) 1.1 (0.4) 0.0004
Creatinine, mg/dL mean (± SD) 1.02 (0.9) 1.0 (0.9) 1.0 (0.8) 0.7
Ferritin ng/mL, mean (± SD)b 785 (922) 551 (624) 1083 (1131) <.0001
C-Reactive Protein mg/dL, mean (± SD)c 49.7 (83.8) 32.6 (2.6) 68.7 (96.6) <.0001
Abbreviation: ACE-2, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus, INR, international normatized























site. Study data were prospectively registered into a web-based
electronic system. All patients were followed until discharge or
death.
2.3. Liver function tests and other exposure variables on
admission and during hospitalization
We  collected epidemiological, demographic, clinical, routine
laboratory, radiological and treatment regimen data on each
patient on admission. Data about medication use before hos-
pitalization was collected, including antibiotics, non-steroidal
anti-inflammatory drugs, acetaminophen and ACE-2 inhibitors.
Laboratory parameters included inflammatory markers such as C-
reactive protein and ferritin levels. Lymphopenia was  considered
when an absolute lymphocyte count was less than 1500/mm3 [15].
To identify specific clinical and laboratory features in patients
with abnormal liver biochemistry parameters, enrolled cases were
categorized into two groups (with or without abnormal liver bio-
chemistry values on admission). We  defined abnormal liver tests as
the elevation of total bilirubin, alanine aminotransferase (ALT) or
alkaline phosphatase (ALP) over the upper limit of normal (ULN).
ULN was defined by the reference value from each institution. Given
the lack of consensus on liver injury classification in COVID-19, we
categorized the degree of ALT elevation as mild (<2 times ULN),
moderate (2–5 times ULN) and severe (>5 times ULN), as it has been
previously reported [9]. ALT was selected to represent liver affec-
tion rather than AST due to the more predominant extra-hepatic





es of routine laboratory tests, including total bilirubin, ALT or ALP,
ere recorded during hospitalization.
.4. COVID-19 severity
The severity of COVID-19 was  classified based on clinical exam-
nation results, symptoms, chest radiography and medical support.
evere COVID-19 cases were defined as those who developed acute
espiratory distress syndrome (ARDS), required intensive care unit
ICU) monitoring, and/or ventilatory support, as reported else-
here [15,16].
.5. Primary outcome, sample size calculations and statistical
nalysis
The primary end-point was  overall mortality. Secondary out-
ome was development of severe COVID-19 during hospitalization.
ased on previously reported mortality rates, a mean rate of 4.8%
as  estimated with a 95% CI 3.9–5.8% [15,17,18]. Assuming a type
 error of 5% (P-value <0.05) and a type II error of 0.10 (90% power),
nd to follow the “1 variable per 10 primary events rule”, to include
t least six independent variables in the final logistic regression
odel, a minimum of 1244 patients would be needed to obtain a
inimum of 60 deaths. In addition, we calculated the proportion of
atients presenting with abnormal liver tests on admission being
1.1% ± 17.1 [2,17,19].
Categorical data were compared using Fisher’s exact test (2-
ailed) or Chi-Square (X2) test as appropriate. Continuous variables
ere reported with a mean (± standard deviation, SD) or median
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Table  2
Clinical outcomes of patients hospitalized for COVID-19.
Liver biochemistries on admission
Total Normal Abnormal P
Variable N = 1611 N = 882 N = 729 Value
Pneumonia, n (%) 864 (53.6) 409 (46.4) 455 (62.4) <.0001
ARDS,  n (%) 660 (40.9) 267 (30.3) 393 (53.9) <.0001
Mild  203 (12.6) 102 (11.6) 101 (13.8)
Moderate 194 (12.0) 66 (7.5) 128 (17.6)
Severe  263 (16.3) 99 (11.2) 164 (22.5)
Multiorgan failure, n (%) 301 (18.7) 102 (11.6) 199 (27.3) <.0001
Concomitant infections, n (%) 340 (22.1) 149 (16.9) 191 (26.2) <.0001
Bacterial 319 (19.8) 138 (15.6) 181 (24.8)
Viral  13 (0.7) 8 (0.9) 5 (0.7)
Fungal 24 (1.6) 10 (1.1) 14 (1.9)
Highest level of care, n (%)
Ward 1046 (64.9) 666 (75.5) 380 (52.3) <.0001
Intermediate ICU 195 (12.2) 66 (7.5) 129 (17.7)
ICU  370 (22.9) 150 (17.0) 220 (30.2)
Any  kind of oxygen support, n (%) 881 (54.7) 372 (42.2) 509 (69.8) <.0001
Intubation, n (%) 292 (18.1) 115 (13.0) 177 (24.3) <.0001



































Vasopressors, n (%) 194 (12.0)
Abbreviations: ARDS, acute respiratory distress syndrome, ICU, intensive care unit.
(Interquartile ranges 25–75%, IQR) and compared with Student’s T
or Mann-Whitney U tests according to their respective distribu-
tions. We  created dummies for ordinal variables were assessed.
Multivariable logistic regression was used to evaluate the asso-
ciation between abnormal liver tests and the odds of death (OR)
with corresponding 95% confidence intervals (CI) estimated. We
first fit univariate models to evaluate crude effects on mortal-
ity of prior medical history, clinical and laboratory findings on
admission, then outcomes and treatments prescribed during hospi-
talization. We  constructed the final multivariable models including
exposure variables with a p-value <0.05 in univariate analysis,
using a step-by-step procedure, in order to develop a parsimonious
model. The final model’s performance was evaluated, including
calibration (Hosmer- Lemeshow goodness-of-fit test) and discrim-
ination power through the area under the receiving operator curve
(AUROC). We estimated margins effects after multivariable logis-
tic regression models and inverse probability weighting (IPW) to
estimate the attributable risk of abnormal liver function tests on
admission, adjusted on the mean values of the other independent
covariates. Data were analyzed with STATA 13.0 (StataCorp, Texas,
USA).
2.6. Sensitivity analysis
Two sensitivity analyses were conducted. As the presence of
the underlying liver disease may  also play a role in the associa-
tion of abnormal liver tests with disease severity, we conducted a
sensitivity analysis excluding patients with prior chronic liver dis-
ease, comprising cirrhosis. Finally, we excluded patients developing
SARS-CoV-2 infection during hospitalization.
3. Results
A cohort of 1611 patients hospitalized with SARS-CoV-2 infec-
tion were enrolled in ALEHś registry. Baseline characteristics of the
study population are displayed in Table 1. Of the entire cohort,
7.7% (CI 6.5–9.2) were admitted for other reasons and acquired
SARS-CoV-2 infection during hospitalization (n = 125), and in
3.0% (CI 2.2–4.0) of these patients diagnosis was made >6 days
after admission (n = 49). Radiological signs on admission showed
pneumonia in 53.6% of the cohort (n = 864). The most frequent
radiological finding was bilateral ground-glass opacities and it was






73 (8.3) 121 (16.6) <.0001
oms reported by patients are presented in Supplementary Table 1.
eventy-one (4.4%) patients were asymptomatic at presentation.
verall, 8.5% (CI 7.1–9.9) of the cohort had chronic liver disease
n = 135) and 3.4% (CI 2.5–4.4) had cirrhosis (n = 55). The most com-
on  etiologies of chronic liver disease were metabolic-associated
atty liver disease in 86 patients, alcohol induced in 14 cases,
hronic hepatitis C in 8 individuals and cholestatic diseases in 10
ubjects.
.1. Clinical features of patients with SARS-CoV-2 and abnormal
iver tests on admission
Abnormal liver biochemistry parameters on admission were
resent on 45.2% of the cohort (CI 42.7–47.7). In those patients
ith chronic liver disease, the proportion of abnormal liver tests
n admission was  71.5% (CI 63.2–78.9). Patients with elevated
LT, total bilirubin and ALP accounted for 35.3%, 6.3% and 19.4%;
espectively. Among patients with elevated ALT, 32.6% of the cases
resented moderate injury (2–5 times ULN) and 10.7% were severe
>5 times ULN). Moreover, the incidence of elevated ALT during hos-
italization was  16.2% (CI 14.4–18.1). When compared to admitted
atients with normal liver tests, the group of patients with elevated
iver biochemistry values on admission were mostly men  (52.9%
s. 63.6%; P < .0001), of older ages (50.7 ± 18.2 vs. 54.2 ± 16.1 years
ld; P = 0.0001), and presenting a higher proportion of hyperten-
ion (27.1% vs. 33.5%; P = 0.006) and body mass index >30 (14.2%
s. 20.8%; P < .0001) (Table 1).
Table 1 also describes laboratory tests results at admission.
ompared to the normal liver biochemistry group, patients with
bnormal tests results had significantly higher platelet counts,
nternational normatized ratio, and a higher proportion of individ-
als presented a lymphocyte count <1500/mm3 and lower levels
f serum albumin. A higher proportion of patients presenting
bnormal liver biochemistry parameters on admission were under
ntibiotic treatment (P < .0001) (Table 1). During hospitalization,
pecific COVID-19 treatment was prescribed in 43.8% of the cohort
n = 705) and was more commonly administered to patients with
bnormal liver tests on admission (p < 0.0001). Other drugs fre-
uently used for hospitalized patients with COVID-19, were also
ignificantly more commonly prescribed to patients who presented
bnormal liver biochemistry values on admission (Supplementary
able 2).
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Table  3
Logistic regression analysis evaluating the primary outcome (death) adjusted for variables significantly associated with a higher risk of mortality on admission.
Baseline exposure variable Mortality rate (95% CI) Adjusted odds ratio (95% CI) P
Age, years
<50 6.4 (4.8−8.4) – –
50–65 14.7 (11.5−18.3) 1.8 (1.2−2.8) 0.003
>65  31.3 (26.9−36.0) 5.4 (3.7−8.0) <.0001
Gender
Male  17.0 (14.6−19.5) 1.5 (1.1−2.1) 0.006
Female 12.6 (10.2−15.4) –
Diabetes mellitus
Yes 27.3 (22.2−32.3) 1.6 (1.1−2.2) 0.007
No 12.5 (10.8−14.4) –
Body mass index >30
Yes 20.9 (16.3−26.2) 1.4 (1.02−2.1) 0.04
No  13.9 (12.0−15.8)
Pneumonia
Yes 21.6 (18.9−24.5) 2.3 (1.6−3.2) <.0001
No  7.6 (5.8−9.8)
Abnormal liver tests





































Note: Calibration (P = 0.07, Hosmer-Lemeshow test). ROC curve 0.76 (CI 0.74−0.78).
3.2. Clinical outcomes of patients with SARS-CoV-2
The cumulative mortality rate in the overall cohort was 15.1%
(CI 13.4–16.9) after a median time since admission of 10.0 (IQR
4.0–18.5) days (n = 244). Clinical outcomes are reported in Table 2.
Severe COVID-19 was developed in 43.8% (CI 41.4–46.3) of the
patients. When considering prognostic demographics and prior
medical history, increasing age, male gender, obesity, cirrhosis, and
diabetes mellitus were significantly associated with a higher risk
of mortality (Supplementary Table 3). Adjusted for age patients
developing ARDS OR 4.0 (CI 2.5–6.5; P < .0001), requiring mechan-
ical ventilation OR 2.9 (CI 2.5–6.5; P < .0001) or with multiorgan
failure OR 5.2 (CI 3.5–7.7; P < .0001) had a higher risk of mortality.
3.3. Association of abnormal liver function tests with death and
severe COVID-19
Mortality was significantly higher in patients with elevated
liver tests results on admission compared to those with nor-
mal  liver tests values (18.7% vs. 12.2%; P < .0001). Patients with
abnormal liver tests on admission required more ICU-level care
(p < .0001), developed more frequently severe COVID-19 during
hospitalization (57.5% vs. 32.4%, P < .0001), and required more days
of hospitalization (10 [IQR 6–16] vs. 7 [IQR 5–12], P < .0001).
We evaluated the effect of abnormal liver biochemistry values
on admission on the risk of mortality adjusted for age, prior med-
ical history, clinical presentation and other laboratory parameters.
Abnormal liver tests on admission were significantly associated
with death (OR 1.4, CI 1.06–1.9; P = 0.02) (Table 3). After exclud-
ing patients with history of chronic liver disease, abnormal liver
tests on admission were still independently associated with death
(OR 1.5, CI 1.1–2.0; P = 0.01], adjusted for age, gender, diabetes, and
pneumonia on admission (Table 4). The model showed adequate
calibration (P = 0.19) with an AUROC of 0.76 (CI 0.73–0.78) (Supple-
mentary Figure 1). Moreover, evaluating the dose-dependent effect
of elevated ALT on admission as a matter of causality, patients with
severe ALT augmentation presented a 2-fold greater odds of death
compared to those with mild ALT elevation (OR 2.0, CI 1.1–3.7);
P = 0.02) (Table 5). In patients without chronic liver disease, the
attributable mortality risk for abnormal liver tests was  3.8% (CI
0.7–7.9%; P = 0.01), considering mean values for other independent
covariates. In the IPW analysis, abnormal liver tests had an absolute
increased mortality rate of 3.4% (CI −0.01 to 7.0) when compared





Finally, we analyzed the association of abnormal liver biochem-
stry values on admission and development of severe COVID-19
uring hospitalization. Patients having abnormal liver tests results
ave a ∼2-fold greater odds of developing severe COVID-19 OR
.4 (CI 1.9–3.1; P < .0001), adjusted for age, male gender, diabetes
ellitus, BMI  > 30 and pneumonia (Supplementary Table 4). The
odel showed an AUROC of 0.83 (CI 0.81–0.85). Sensitivity analysis
xcluding patients with prior chronic liver disease, abnormal liver
ests on admission were still independently associated with severe
OVID-19 of 2.6 (CI 1.9–3.3; P < .0001), adjusted for age, gender,
iabetes, and pneumonia on admission (Table 6).
. Discussion
Results from this large Latin America prospective cohort study
escribe that almost half of the patients hospitalized with COVID-
9 presented abnormal liver tests on admission. However, most
atients just showed mild liver biochemistry parameters elevation
t the early stage of SARS-CoV-2 infection. Compared to patients
ith normal liver tests on admission, those who had abnormal
iver test results were more frequently admitted to ICU, had a sig-
ificantly higher probability of developing severe COVID-19, and
igher odds of mortality, highlighting its importance as a marker
f disease severity.
Wide variability in liver enzymes deviations in patients with
OVID-19 can be secondary to the different considered cutoff val-
es and to the time of liver tests evaluation. In our study, we  used
iver enzymes cutoffs as defined by the ULN of each participat-
ng institution. We  intended to describe the impact of liver injury
t the early stages of the disease. Thus, while most studies con-
emplated peak liver test values during hospitalization, we used
iver test abnormalities at hospital admission [9,20,21]. The fre-
uency of liver enzymes elevation during SARS-CoV-2 infection
s directly related to the progression of the severity of the dis-
ase. Some authors have recommended longitudinal monitoring
f hepatic transaminases, particularly in patients receiving clini-
al research treatments [21]. At advanced stages of COVID-19, liver
est alterations can have a multifactorial origin. The combination
f multiple prescribed drugs and the SARS-CoV-2-induced systemic
nflammatory response can lead to liver injury. Thus, evaluating the
mpact of peak liver test abnormalities during hospitalization can
rovide misleading conclusions.
In our study, we  found that abnormal liver biochemistry val-
es on admission were significantly associated with outcomes
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Table  4
Logistic regression analysis for the primary outcome (death) based on data at admission, excluding patients with chronic liver disease or cirrhosis (n = 137).
Baseline exposure variable Mortality rate (95% CI) Adjusted odds ratio (95% CI) P
Age, years
<50 6.1 (4.5−8.1) – –
50–65  12.7 (9.7−16.4) 1.6 (1.02−2.5) 0.04
>65  31.6 (26.7−36.6) 5.4 (3.6−8.0) <.0001
Gender
Male  16.2 (13.8−18.9) 1.6 (1.1−2.2) 0.007
Female 11.7 (9.3−14.5) –
Diabetes mellitus
Yes 27.7 (22.1−33.9) 1.8 (1.3−2.6) 0.001
No  11.7 (10.0−13.6) –
Pneumonia
Yes  20.5 (17.7−23.5) 2.2 (1.6−3.2) <.0001
No  7.3 (5.5−9.5) –
Abnormal Liver tests
Yes 17.9 (15.0−21.1) 1.5 (1.1−2.0) 0.01
No  11.6 (9.5−14.0) –
Note: Calibration (P = 0.19, Hosmer-Lemeshow test). ROC curve 0.76 (CI 0.73−0.78).
Table 5
Logistic regression analysis for the primary outcome (death) evaluating the severity of ALT elevation on admission. Odds Ratios (OR).
Baseline exposure variable Mortality rate (95% CI) Adjusted OR (95% CI) P
Age, years
<50 6.4 (4.8−8.4) – –
50–65 14.7 (11.5−18.3) 1.8 (1.2−2.7) 0.004
>65  31.3 (26.9−36.0) 5.4 (3.7−8.0) <.0001
Gender
Male 12.6 (10.2−15.4) 1.5 (1.1−2.1) 0.007
Female 17.0 (14.6−19.5) –
Diabetes mellitus
Yes 27.3 (22.2−32.3) 1.5 (1.1−2.1) 0.02
No  12.5 (10.8−14.4) –
Obesity
Yes  20.9 (16.3−26.2) 1.4 (1.02−2.1) 0.04
No  13.9 (12.0−15.8) –
Cirrhosis
Yes  38.2 (25.4−52.3) 2.2 (1.2−4.0) 0.01
No  14.3 (12.6−16.2) –
Pneumonia
Yes  21.6 (18.9−24.5) 2.3 (1.6−3.2) <.0001
No  7.6 (5.8−9.8) –
ALT  elevation
None – – –
Mild  17.9 (14.3−22.0) 1.3 (0.9−1.8) 0.2
Moderate 18.1 (13.4−23.5) 1.4 (0.9−2.1) 0.1
Severe 24.4 (15.3−35.4) 2.0 (1.1−3.7) 0.02
Note: Calibration (P = 0.27, Hosmer-Lemeshow test). ROC curve 0.77 (CI 0.75−0.79).
Table 6
Logistic regression analysis for the secondary outcome (severe COVID-19) excluding patients with chronic liver disease or cirrhosis (n = 137). Odds Ratios (OR).
Baseline exposure variable Severe COVID-19 (95% CI) Crude OR (95% CI) P Adjusted OR (95% CI) P
Age, years
<50 28.9 (25.6−32.4) −1.03 (1.02−1.04) – – –
50–65  50.7 (45.8−55.7) 2.5 (2.0−3.3) <.0001 1.5 (1.1−2.1) 0.005
>65  59.4 (54.2−64.5) 3.6 (2.8−4.7) <.0001 2.7 (1.9−3.8) <.0001
Gender
Male  48.5 (45.1−51.9) 1.8 (1.4−2.2) <.0001 1.7 (1.3−2.5) <.0001
Female 34.4 (30.7−38.3) – –
Diabetes mellitus
Yes 63.4 (57.0−69.6) 2.8 (2.1−3.7) <.0001 1.6 (1.1−2.3) 0.007
No  38.5 (35.8−41.3) – –
Obesity
Yes  70.3 (64.1−76.0) 4.0 (3.0−5.4) <.0001 3.2 (2.3−4.7) <.0001
No  37.2 (34.5−40.0) – –
Pneumonia
Yes  65.6 (62.1−68.9) 9.5 (7.4−12.2) <.0001 7.2 (5.5−9.4) <.0001
No  16.7 (14.0−19.7) – –
Abnormal liver tests
Yes 57.2 (53.2−61.1) 2.8 (2.3−3.4) <.0001 2.6 (1.9−3.3) <.0001
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during hospitalization such as prolonged length of stay, devel-
opment of severe COVID-19, and more importantly, death. A
previous study from China reported similar findings describing
an association between mortality and abnormal liver tests on
admission [22]. However, in that study, data were retrospectively
collected; patients in the abnormal liver tests group presented a
significantly higher proportion of chronic liver disease. Lei at al.
analyzed a large retrospective cohort from China, including more
than 5700 patients [20]. In this interesting study, the authors
concluded that the increase of AST levels had a higher correla-
tion with mortality than other liver injury indicators. We  believe
that the inclusion of AST as a marker of liver injury is arguable
due to the potential extra-hepatic sources of AST rendering it
less liver-specific. To avoid potential confounders, we did not
include AST in our definition of abnormal liver tests, and we
performed a sensitivity analysis excluding patients with chronic
liver disease, still observing a significant association to worse out-
comes.
Compared to previous studies, our cohort includes a younger
population with a lower proportion of associated comorbidities
[1,9]. We  can speculate that this is the consequence of including
patients with mild symptoms of COVID-19 who  were hospital-
ized because they could not isolate themselves at their homes.
This allowed us to evaluate the whole spectrum of SARS-CoV-
2 infection, from mild cases to those who developed severe
COVID-19 and died. Therefore, the prognostic value of liver bio-
chemistry tests would acquire greater relevance. We  believe that
liver function tests should be included in the initial evaluation
of a COVID-19 patient, and may  help physicians decide hos-
pitalization or prompt referral irrespectively from radiological
pneumonia.
The major strength of our study is the inclusion of a large
and geographically diverse population, in which data collec-
tion and outcome measures have been prospectively collected.
However, we must acknowledge certain limitations in the inter-
pretation of the results of our study. First, the recommended
cutoff for defining moderate or severe liver injury is debatable
[23,24]. However, we are facing a new disease and its impact
on the liver is not yet completely understood. We  then graded
liver injury by applying cutoff values previously reported in this
disease [9]. Second, we did not include other inflammatory mark-
ers in our final model. We  intended to include affordable and
feasible blood tests, together with clinically relevant variables,
to build a parsimonious model. Finally, although SARS-CoV-2
infection was diagnosed as per the local site-specific protocol, algo-
rithms followed their local epidemiological situation and available
resources.
In summary, in this large multicenter cohort from Latin Amer-
ica, abnormal liver tests on admission were associated with most
severe clinical outcomes, including death. This accessible test may
be another useful tool to identify patients at increased risk of
developing severe COVID-19 who require hospitalization. More-
over, future clinical trials evaluating COVID-19 targeted therapies
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